Cargando…
Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
SIMPLE SUMMARY: EGFR T790M-positive clones expand in treated by EGFR inhibitors. C-MET amplified clones expand in HCC827 lung cancer cells treated by EGFR inhibitors. Early on-treatment kinetics of the resistance-related gene predict the resistance mechanism. ABSTRACT: Background: Prediction of resi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946020/ https://www.ncbi.nlm.nih.gov/pubmed/35326664 http://dx.doi.org/10.3390/cancers14061512 |
_version_ | 1784674094004830208 |
---|---|
author | Choi, Yu-ra Cho, Youngnam Park, Seog-Yun Kim, Sunshin Shin, Myungsun Choi, Yongdoo Shin, Dong Hoon Han, Ji-Youn Lee, Youngjoo |
author_facet | Choi, Yu-ra Cho, Youngnam Park, Seog-Yun Kim, Sunshin Shin, Myungsun Choi, Yongdoo Shin, Dong Hoon Han, Ji-Youn Lee, Youngjoo |
author_sort | Choi, Yu-ra |
collection | PubMed |
description | SIMPLE SUMMARY: EGFR T790M-positive clones expand in treated by EGFR inhibitors. C-MET amplified clones expand in HCC827 lung cancer cells treated by EGFR inhibitors. Early on-treatment kinetics of the resistance-related gene predict the resistance mechanism. ABSTRACT: Background: Prediction of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) remains challenging. Thus, we investigated whether resistant cancer cells that expand shortly after EGFR-TKI treatment would eventually cause the resistant phenotype. Methods: We generated two EGFR-mutant lung cancer cell lines resistant to gefitinib (PC9GR and HCC827GR). The parent cell lines were exposed to short-term treatment with gefitinib or paclitaxel and then were assessed for EGFR T790M mutation and C-MET expression. These experiments were repeated in vivo and in clinically relevant patient-derived cell (PDC) models. For validation in clinical cases, we measured these gene alterations in plasma circulating tumor DNA (ctDNA) before and 8 weeks after starting EGFR-TKIs in four patients with EGFR-mutant lung cancer. Results: T790M mutation was only detected in the PC9GR cells, whereas C-MET amplification was detected in the HCC827GR cells. The T790M mutation level significantly increased in PC9 cells after short-term treatment with gefitinib but not in the paclitaxel. C-MET mRNA expression was only significantly increased in gefitinib-treated HCC827 cells. We confirmed that the C-MET copy number in HCC827 cells that survived after short-term gefitinib treatment was significantly higher than that in dead HCC827 cells. These findings were reproduced in the in vivo and PDC models. An early on-treatment increase in the plasma ctDNA level of these gene alterations was correlated with the corresponding resistance mechanism to EGFR-TKIs, a finding that was confirmed in post-treatment tumor tissues. Conclusions: Early on-treatment kinetics in resistance-related gene alterations may predict the final mechanism of EGFR-TKI resistance. |
format | Online Article Text |
id | pubmed-8946020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89460202022-03-25 Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors Choi, Yu-ra Cho, Youngnam Park, Seog-Yun Kim, Sunshin Shin, Myungsun Choi, Yongdoo Shin, Dong Hoon Han, Ji-Youn Lee, Youngjoo Cancers (Basel) Article SIMPLE SUMMARY: EGFR T790M-positive clones expand in treated by EGFR inhibitors. C-MET amplified clones expand in HCC827 lung cancer cells treated by EGFR inhibitors. Early on-treatment kinetics of the resistance-related gene predict the resistance mechanism. ABSTRACT: Background: Prediction of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) remains challenging. Thus, we investigated whether resistant cancer cells that expand shortly after EGFR-TKI treatment would eventually cause the resistant phenotype. Methods: We generated two EGFR-mutant lung cancer cell lines resistant to gefitinib (PC9GR and HCC827GR). The parent cell lines were exposed to short-term treatment with gefitinib or paclitaxel and then were assessed for EGFR T790M mutation and C-MET expression. These experiments were repeated in vivo and in clinically relevant patient-derived cell (PDC) models. For validation in clinical cases, we measured these gene alterations in plasma circulating tumor DNA (ctDNA) before and 8 weeks after starting EGFR-TKIs in four patients with EGFR-mutant lung cancer. Results: T790M mutation was only detected in the PC9GR cells, whereas C-MET amplification was detected in the HCC827GR cells. The T790M mutation level significantly increased in PC9 cells after short-term treatment with gefitinib but not in the paclitaxel. C-MET mRNA expression was only significantly increased in gefitinib-treated HCC827 cells. We confirmed that the C-MET copy number in HCC827 cells that survived after short-term gefitinib treatment was significantly higher than that in dead HCC827 cells. These findings were reproduced in the in vivo and PDC models. An early on-treatment increase in the plasma ctDNA level of these gene alterations was correlated with the corresponding resistance mechanism to EGFR-TKIs, a finding that was confirmed in post-treatment tumor tissues. Conclusions: Early on-treatment kinetics in resistance-related gene alterations may predict the final mechanism of EGFR-TKI resistance. MDPI 2022-03-15 /pmc/articles/PMC8946020/ /pubmed/35326664 http://dx.doi.org/10.3390/cancers14061512 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Choi, Yu-ra Cho, Youngnam Park, Seog-Yun Kim, Sunshin Shin, Myungsun Choi, Yongdoo Shin, Dong Hoon Han, Ji-Youn Lee, Youngjoo Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors |
title | Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors |
title_full | Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors |
title_fullStr | Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors |
title_full_unstemmed | Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors |
title_short | Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors |
title_sort | early on-treatment prediction of the mechanisms of acquired resistance to egfr tyrosine kinase inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946020/ https://www.ncbi.nlm.nih.gov/pubmed/35326664 http://dx.doi.org/10.3390/cancers14061512 |
work_keys_str_mv | AT choiyura earlyontreatmentpredictionofthemechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitors AT choyoungnam earlyontreatmentpredictionofthemechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitors AT parkseogyun earlyontreatmentpredictionofthemechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitors AT kimsunshin earlyontreatmentpredictionofthemechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitors AT shinmyungsun earlyontreatmentpredictionofthemechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitors AT choiyongdoo earlyontreatmentpredictionofthemechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitors AT shindonghoon earlyontreatmentpredictionofthemechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitors AT hanjiyoun earlyontreatmentpredictionofthemechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitors AT leeyoungjoo earlyontreatmentpredictionofthemechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitors |